Effect of denosumab on osteolytic lesion activity after total hip arthroplasty: a single-centre, randomised, double-blind, placebo-controlled, proof of concept trial

Mohit M. Mahatma; Raveen L. Jayasuriya; David Hughes; Nigel Hoggard; Simon C. Buckley; Andrew Gordon; Andrew J. Hamer; Mohammed W. Tomouk; Robert M. Kerry; Richard Eastell; Jeremy M. Wilkinson

doi:10.1016/S2665-9913(20)30394-5

Effect of denosumab on osteolytic lesion activity after total hip arthroplasty: a single-centre, randomised, double-blind, placebo-controlled, proof of concept trial

Mohit M. Mahatma, Raveen L. Jayasuriya, David Hughes, Nigel Hoggard, Simon C. Buckley, Andrew Gordon, Andrew J. Hamer, Mohammed W. Tomouk, Robert M. Kerry, Richard Eastell, Jeremy M. Wilkinson^*

^*Corresponding author for this work

Research output: Contribution to journal › Article › peer-review

6 Citations (Scopus)

Original language	English
Pages (from-to)	e195-e203
Journal	The Lancet Rheumatology
Volume	3
Issue number	3
DOIs	https://doi.org/10.1016/S2665-9913(20)30394-5
Publication status	Published (VoR) - Mar 2021

Funding

This study was funded by Amgen. Denosumab and placebo were provided by Amgen free of charge. We thank all the participants in our trial. We thank Angela Green, the study research nurse at Sheffield Teaching Hospitals NHS Foundation Trust, for managing the participant study visits and doing study-related procedures; Orla Gallagher, histology technician, for biopsy processing and making the immunohistochemistry measurements; Maggie Glover, histology technician, for immunohistochemistry staining; and Fatma Gossiel, bone biochemistry technician, for assisting with the biochemical marker measurements.

Access to Document

10.1016/S2665-9913(20)30394-5

Cite this

Mahatma, M. M., Jayasuriya, R. L., Hughes, D., Hoggard, N., Buckley, S. C., Gordon, A., Hamer, A. J., Tomouk, M. W., Kerry, R. M., Eastell, R., & Wilkinson, J. M. (2021). Effect of denosumab on osteolytic lesion activity after total hip arthroplasty: a single-centre, randomised, double-blind, placebo-controlled, proof of concept trial. The Lancet Rheumatology, 3(3), e195-e203. https://doi.org/10.1016/S2665-9913(20)30394-5

@article{6d5718d6b7df448eb0b8d5dac4ca10b0,

title = "Effect of denosumab on osteolytic lesion activity after total hip arthroplasty: a single-centre, randomised, double-blind, placebo-controlled, proof of concept trial",

author = "Mahatma, \{Mohit M.\} and Jayasuriya, \{Raveen L.\} and David Hughes and Nigel Hoggard and Buckley, \{Simon C.\} and Andrew Gordon and Hamer, \{Andrew J.\} and Tomouk, \{Mohammed W.\} and Kerry, \{Robert M.\} and Richard Eastell and Wilkinson, \{Jeremy M.\}",

note = "Funding Information: This study was funded by Amgen. Denosumab and placebo were provided by Amgen free of charge. We thank all the participants in our trial. We thank Angela Green, the study research nurse at Sheffield Teaching Hospitals NHS Foundation Trust, for managing the participant study visits and doing study-related procedures; Orla Gallagher, histology technician, for biopsy processing and making the immunohistochemistry measurements; Maggie Glover, histology technician, for immunohistochemistry staining; and Fatma Gossiel, bone biochemistry technician, for assisting with the biochemical marker measurements. Publisher Copyright: {\textcopyright} 2021 Elsevier Ltd",

year = "2021",

month = mar,

doi = "10.1016/S2665-9913(20)30394-5",

language = "English",

volume = "3",

pages = "e195--e203",

journal = "The Lancet Rheumatology",

issn = "2665-9913",

publisher = "Elsevier",

number = "3",

}

Mahatma, MM, Jayasuriya, RL, Hughes, D, Hoggard, N, Buckley, SC, Gordon, A, Hamer, AJ, Tomouk, MW, Kerry, RM, Eastell, R & Wilkinson, JM 2021, 'Effect of denosumab on osteolytic lesion activity after total hip arthroplasty: a single-centre, randomised, double-blind, placebo-controlled, proof of concept trial', The Lancet Rheumatology, vol. 3, no. 3, pp. e195-e203. https://doi.org/10.1016/S2665-9913(20)30394-5

TY - JOUR

T1 - Effect of denosumab on osteolytic lesion activity after total hip arthroplasty

T2 - a single-centre, randomised, double-blind, placebo-controlled, proof of concept trial

AU - Mahatma, Mohit M.

AU - Jayasuriya, Raveen L.

AU - Hughes, David

AU - Hoggard, Nigel

AU - Buckley, Simon C.

AU - Gordon, Andrew

AU - Hamer, Andrew J.

AU - Tomouk, Mohammed W.

AU - Kerry, Robert M.

AU - Eastell, Richard

AU - Wilkinson, Jeremy M.

N1 - Funding Information: This study was funded by Amgen. Denosumab and placebo were provided by Amgen free of charge. We thank all the participants in our trial. We thank Angela Green, the study research nurse at Sheffield Teaching Hospitals NHS Foundation Trust, for managing the participant study visits and doing study-related procedures; Orla Gallagher, histology technician, for biopsy processing and making the immunohistochemistry measurements; Maggie Glover, histology technician, for immunohistochemistry staining; and Fatma Gossiel, bone biochemistry technician, for assisting with the biochemical marker measurements. Publisher Copyright: © 2021 Elsevier Ltd

PY - 2021/3

Y1 - 2021/3

UR - https://www.scopus.com/pages/publications/85099979170

UR - https://www.scopus.com/inward/citedby.url?scp=85099979170&partnerID=8YFLogxK

U2 - 10.1016/S2665-9913(20)30394-5

DO - 10.1016/S2665-9913(20)30394-5

M3 - Article

AN - SCOPUS:85099979170

SN - 2665-9913

VL - 3

SP - e195-e203

JO - The Lancet Rheumatology

JF - The Lancet Rheumatology

IS - 3

ER -

Effect of denosumab on osteolytic lesion activity after total hip arthroplasty: a single-centre, randomised, double-blind, placebo-controlled, proof of concept trial

Funding

Access to Document

Other files and links

Fingerprint

Cite this